wellrank.ai
Alora logo

Alora

First cited by AI Jun 12, 2026
alora.info

Surfaced organically in AI answers about bhrt. Not yet profiled.

AI Visibility

Visibility trend

Menopause and women's health, daily share of AI answers mentioning Alora, through Jun 13, 2026.

8.3%

Avg position when mentioned: 4.0

By engine

Where Alora is strong, and where it is invisible.

  • ChatGPT
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 2 positive mentions
  • 0 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Alora

ChatGPTJun 13, 2026, 11:06 UTC
Bioidentical hormones vs standard HRT: what is the difference?

Short answer “Bioidentical” hormones are molecules formulated to be chemically identical to the hormones your body makes (usually estradiol and progesterone). “Standard” HRT (hormone replacement therapy) includes both bioidentical (FDA‑approved) products and older synthetic or animal‑derived products; the main practical difference most people face is whether the product is an FDA‑reviewed drug or a custom‑compounded preparation from a pharmacy. There’s no good evidence that custom‑compounded “bioidentical hormone therapy” is safer or more effective than FDA‑approved HRT. Compounded products can have variable potency and lack FDA oversight. What each term means Bioidentical hormones: chemically identical to human hormones (example: 17β‑estradiol, micronized progesterone). These can be made as FDA‑approved products (tablets, patches, gels, vaginal rings) or as custom compounds from compounding pharmacies. Standard HRT: a broader category that includes FDA‑approved estradiol products (patches, gels, pills) and FDA‑approved micronized progesterone, synthetic progestins (e.g., medroxyprogesterone acetate) and animal‑derived estrogens (e.g., conjugated equine estrogens). These are manufactured drugs with standardized dosing and safety testing. Examples (brand names and why they matter) FDA‑approved, bioidentical examples: Prometrium (micronized progesterone) — FDA‑approved bioidentical progesterone used to protect the uterus when systemic estrogen is given. Estradiol patches/gels: Vivelle‑Dot, Climara, Alora — deliver 17β‑estradiol transdermally and have standardized dosing. Bijuva — an FDA‑approved combined oral capsule containing estradiol and progesterone (bioidentical combination). Vaginal products: Estrace cream, Vagifem tablets, Estring/Femring (vaginal ring/locally acting estradiol) — useful for local symptoms with lower systemic exposure. Non‑bioidentical / synthetic examples: Premarin (conjugated equine estrogens) — animal‑derived estrogen mixture, historically common. Provera (medroxyprogesterone acetate) — synthetic progestin. Compounded “bioidentical” creams or troches: made by compounding pharmacies to a custom dose. These are not FDA‑approved and product strength/purity can vary. If you choose this route, use a PCAB‑accredited compounding pharmacy (look up PCAB accreditation). Examples of well‑known compounding suppliers/pharmacies in the U.S. include Wedgewood Pharmacy and Fagron (as suppliers/compounding networks) — but check current accreditation and reputation locally. Safety, evidence, and regulation FDA‑approved HRT products have known dosages, standardized manufacturing, and have been evaluated for quality and safety. Long‑term risks (breast cancer, cardiovascular disease, stroke, blood clots) depend on the type of hormone, dose, route (oral vs transdermal), whether progesterone is given, and your personal risk factors. The Women’s Health Initiative (WHI) showed increased risks with combined conjugated equine estrogen + medroxyprogesterone in older participants. Risk profiles differ with estradiol vs conjugated equine estrogens and with micronized progesterone vs synthetic progestins. Compounded bioidenticals: proponents claim “natural” = safer, but there’s no high‑quality evidence that compounded BHRT reduces long‑term risks. Because compounded products aren’t FDA‑reviewed, potency and purity can be inconsistent and they may lack safety data. Testing and monitoring Beware of clinics that base dosing on saliva tests or single spot hormone levels — hormone levels fluctuate and those tests are not reliable for routine dosing. Appropriate approach: evaluate symptoms, medical history, family history (breast cancer, clotting disorders), baseline screening (mammogram, blood pressure, lipids, glucose as needed), then choose a therapy and monitor symptoms and side effects regularly. Use the lowest effective dose for the shortest needed time, and use uterine protection (progesterone or a progestin) if you have a uterus and take systemic estrogen. Practical guidance / when to prefer one option If you want the assurance of standardized dosing and known safety data, choose FDA‑approved products (e.g., estradiol patches, oral estradiol, Prometrium, Bijuva). Consider local vaginal estrogen (Estrace cream, Vagifem, Estring) for primarily vaginal dryness/urginal symptoms — these have lower systemic exposure. If you have unusual needs (allergies to excipients, very specific dose requests), a compounding pharmacy can be considered — but insist on a reputable, PCAB‑accredited pharmacy and understand the tradeoffs (no FDA approval, variable evidence). Discuss the choice with a clinician experienced in menopause/HRT care (board‑certified gynecologist or endocrinologist). Trusted resources: North American Menopause Society (NAMS), Mayo Clinic, Cleveland Clinic for patient information and evidence‑based guidance. Bottom line “Bioidentical” describes the molecular structure of the hormone; the clinically important distinction is whether the product is an FDA‑approved, standardized medication or a custom, non‑FDA‑regulated compounded product. FDA‑approved bioidentical options (Prometrium, estradiol patches/creams, Bijuva) give predictable dosing and safety data; compounded BHRT may be useful in select cases but carries more uncertainty. Talk with a clinician about your symptoms, risks, and monitoring plan before starting HRT.

Mentioned in position 4 of 13

Read full answer with sources →
ChatGPTJun 12, 2026, 10:16 UTC
Is BHRT safe? What do doctors say about bioidentical hormones?

Short answer: Bioidentical hormones can be safe and effective when prescribed and monitored by a clinician, but the safety depends on which products are used, who prescribes them, and your personal health risks. Major medical societies caution against custom-compounded “bioidentical” mixtures and recommend FDA‑approved formulations when hormone therapy is needed. Key points doctors and medical societies emphasize “Bioidentical” simply means the molecule is chemically identical to human hormones (e.g., estradiol, progesterone). That label does not guarantee safety or superiority. FDA‑approved bioidentical products (standard prescription estradiol, micronized progesterone) are regulated for dose, purity and labeling. These are the preferred option for most clinicians. Custom-compounded BHRT made by compounding pharmacies is a concern because of inconsistent dosing, lack of standard testing, and weak evidence for claimed advantages. The FDA, ACOG, Endocrine Society and North American Menopause Society (NAMS) have warned about these issues. Risks seen with hormone therapy (both conventional and bioidentical) include increased risk of blood clots, stroke, and — depending on type/duration — possible effects on breast cancer risk and cardiovascular outcomes. Benefits include relief of hot flashes, vaginal symptoms, and bone protection. Individual risk/benefit depends on age, years since menopause, personal/family history of clotting, breast cancer, heart disease, etc. Practical clinical points doctors use If you have a uterus, you need progestogen with systemic estrogen to prevent endometrial hyperplasia. Transdermal estradiol (patches/gels) is often chosen because some evidence suggests lower risk of venous thromboembolism than oral estrogen. Micronized progesterone (versus some synthetic progestins) is preferred by many clinicians for certain safety/tolerability reasons. Routine saliva hormone testing to dose BHRT is not supported by evidence; serum testing and symptom-guided dosing are usual approaches. Testosterone for women can help low libido in selected cases but is generally off‑label and requires specialist oversight; compounded testosterone is commonly used but evidence is limited. FDA‑approved products commonly used (examples clinicians often prescribe) Estradiol (oral): Estrace — FDA‑approved estradiol tablet for menopausal symptoms. Estradiol patches: Vivelle‑Dot, Climara, Alora — transdermal patches give steady dosing and may lower clot risk. Local vaginal products: Estring (ring), Vagifem (vaginal tablet) — treat genitourinary symptoms with low systemic exposure. Micronized progesterone: Prometrium — an FDA‑approved “bioidentical” progesterone many doctors prefer. Testosterone: no widely accepted FDA product labeled for general female libido therapy in the U.S.; some clinicians prescribe low‑dose male formulations off‑label or refer to specialists. Services and resources to consider See a menopause specialist or a clinician trained in hormone management: centers at Mayo Clinic, Cleveland Clinic, or a NAMS‑recognized menopause practitioner are good choices. NAMS (North American Menopause Society) — evidence‑based guidance and clinician directory. If you prefer telemedicine, look for telehealth clinics with certified menopause providers (e.g., some services within Maven Clinic or large academic centers’ telehealth programs). What you can do next Talk with your primary care doctor, gynecologist or a menopause specialist about symptoms and your health history (clotting, heart disease, breast cancer). Ask for FDA‑approved options first (estradiol and micronized progesterone) and discuss routes (transdermal vs oral). Avoid compounded BHRT unless there is a clear medical reason and the compounding pharmacy is accredited and your prescriber documents why a custom product is necessary. Get baseline screening (mammogram as appropriate, blood pressure, discuss clotting history) and plan follow‑up to monitor benefit and side effects. If you want, tell me your age, symptoms, medical history (especially personal/family clotting, breast cancer, cardiovascular disease), and whether you’ve used hormones before — I can give more tailored information and suggest specific questions to bring to your clinician.

Mentioned in position 4 of 10

Read full answer with sources →

Public AI visibility history

Daily rank of Alora on our buyer intent questions, per category. A dash means the engines did not cite Alora at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Menopause and women's health#29
BHRT#93

TL;DR

Alora is a prescription transdermal estradiol patch used in hormone replacement therapy, including bioidentical hormone replacement therapy (BHRT), and is manufactured by Searchlight Pharma for the Canadian market. It delivers estradiol through the skin to relieve menopausal symptoms and is available by prescription through Canadian pharmacies. According to WellRank's latest index, Alora currently ranks twelfth in the Menopause and Women's Health category with 8% AI visibility, and all recorded AI mentions in the WellRank corpus carry a positive tone.

Company Overview

Alora is a branded estradiol transdermal patch product rather than a standalone company; it is marketed by Searchlight Pharma, a Canadian specialty pharmaceutical company focused on prescription therapeutics. The product fits within the broader prescription HRT market and is dispensed through licensed Canadian pharmacies. The business model is a traditional pharmaceutical commercialization model, relying on physician prescribing and pharmacy distribution rather than direct-to-consumer sales.

Product Features

  • Transdermal estradiol patch delivering continuous low-dose estrogen through the skin
  • Available in multiple dose strengths to allow individualized prescribing
  • Twice-weekly application schedule typical for the patch format
  • Used as part of BHRT regimens, as estradiol is bioidentical to endogenous human estrogen
  • Prescription-only product dispensed through licensed pharmacies

Target Market

Alora is intended for women experiencing menopausal or perimenopausal symptoms such as hot flashes, night sweats, and vaginal atrophy, and for those requiring estrogen therapy for other clinically indicated reasons. Its primary geography is Canada, where it is an approved prescription product. Prescribers include gynecologists, internists, and family physicians managing women's hormonal health.

Buyer Personas

  • A perimenopausal woman in her late forties whose physician has recommended a transdermal estrogen option to manage moderate-to-severe hot flashes.
  • A postmenopausal woman who prefers a patch over oral HRT due to concerns about first-pass liver metabolism or pill compliance.
  • A patient working with an integrative or BHRT-focused physician who specifically requests bioidentical estradiol in a patch format.
  • A Canadian pharmacist or HRT clinic counselor researching patch options to recommend alongside progestogen therapy for patients with an intact uterus.

Funding & Performance

Alora is a prescription pharmaceutical product commercialized by Searchlight Pharma; detailed funding, valuation, or revenue figures for either the product line or its parent company are not publicly disclosed.

Recent Developments

Alora has maintained a presence in Canadian HRT prescribing as interest in bioidentical and transdermal hormone options has grown among both patients and clinicians. General market trends toward personalized menopause care and increased public discussion of BHRT have raised awareness of transdermal estradiol patches like Alora, though specific recent product launches or formulation changes are not widely reported in public sources.

Competitive Landscape

In AI-generated answers tracked by WellRank, Alora surfaces alongside established transdermal and vaginal estrogen brands including Vivelle-Dot, Climara, Estrace, Estring, and Vagifem, as well as oral progestogen products such as Prometrium and Provera. Compounding pharmacy options like Wedgewood Pharmacy also appear in the same AI answer contexts, reflecting the broader competitive set of both branded and compounded BHRT options that clinicians and patients evaluate together. Alora's Canadian market positioning distinguishes it from several US-centric competitors in this co-mention group.

Alora vs the brands AI recommends alongside it

The real competitive set in Menopause and women's health: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Alora logo
AloraThis brand
#29
8.3%
Climara logo
Climara

2 shared answers

#7
16.7%
Estrace logo
Estrace

2 shared answers

#8
16.7%
Estring logo
Estring

2 shared answers

#27
8.3%
Prometrium logo
Prometrium

2 shared answers

#9
16.7%

Email me when overtakes Alora

One email the day the ranks flip. Nothing else.

User Sentiment

WellRank's corpus records two AI mentions of Alora, both carrying a positive tone and none flagged as neutral or cautious, suggesting that when AI engines reference the product it is framed favorably in the context of menopause and BHRT discussions. Public patient sentiment around transdermal estradiol patches broadly tends to be positive among users who report good tolerability and convenience compared to oral HRT, though specific large-scale review data for the Alora brand is not publicly aggregated in a widely cited source.

Pricing

As a prescription pharmaceutical product, Alora's cost to patients depends on Canadian provincial drug benefit coverage, private insurance plans, and individual pharmacy dispensing fees; exact retail pricing is not published centrally and varies by coverage and dispensing location.

Sources cited around Alora

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Alora weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Alora? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.